Jazz Cost Of Revenue vs Reconciled Depreciation Analysis

JAZZ Stock

USD 108.99 1.50 1.36%

Jazz Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Jazz Pharmaceuticals PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jazz Pharmaceuticals PLC is a good investment. Please check the relationship between Jazz Pharmaceuticals Cost Of Revenue and its Reconciled Depreciation accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Cost Of Revenue vs Reconciled Depreciation

Cost Of Revenue vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jazz Pharmaceuticals PLC Cost Of Revenue account and Reconciled Depreciation. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Jazz Pharmaceuticals' Cost Of Revenue and Reconciled Depreciation is 0.8. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Jazz Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Jazz Pharmaceuticals' Cost Of Revenue and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Jazz Pharmaceuticals PLC are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Cost Of Revenue i.e., Jazz Pharmaceuticals' Cost Of Revenue and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

0.8

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Jazz Pharmaceuticals PLC income statement and represents the costs associated with goods and services Jazz Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Reconciled Depreciation

Most indicators from Jazz Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jazz Pharmaceuticals PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Selling General Administrative is likely to rise to about 1.4 B in 2024, despite the fact that Tax Provision is likely to grow to (177.5 M).

	2021	2022	2023	2024 (projected)
Gross Profit	2.7B	3.1B	2.8B	2.9B
Total Revenue	3.1B	3.7B	3.8B	4.0B

Gross Profit Total Revenue

Jazz Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Common Stock Shares Outstanding		0.43	0.34	0.38	0.32	0.53	0.36	0.41	0.3	0.4	0.35	0.51	0.42	0.19	0.32	0.35	0.4	0.41	0.49	0.12	0.36	0.22	0.29	0.53	0.36	0.36
Total Assets	0.43		0.98	0.97	0.9	0.91	0.94	0.79	0.97	0.75	0.96	0.69	0.99	0.71	0.89	0.98	0.61	0.98	0.99	0.3	0.98	0.89	0.95	0.98	0.98	0.95
Short Long Term Debt Total	0.34	0.98		0.98	0.91	0.81	0.95	0.7	0.99	0.61	0.97	0.65	0.97	0.73	0.87	1.0	0.51	0.96	0.96	0.17	0.99	0.94	0.96	0.94	1.0	0.9
Other Current Liab	0.38	0.97	0.98		0.94	0.83	0.9	0.7	0.96	0.65	0.97	0.73	0.95	0.76	0.93	0.97	0.61	0.98	0.96	0.26	0.96	0.89	0.98	0.96	0.98	0.91
Total Current Liabilities	0.32	0.9	0.91	0.94		0.79	0.83	0.54	0.87	0.61	0.92	0.79	0.86	0.92	0.92	0.87	0.71	0.95	0.88	0.38	0.86	0.77	0.97	0.9	0.9	0.87
Total Stockholder Equity	0.53	0.91	0.81	0.83	0.79		0.8	0.86	0.78	0.93	0.81	0.7	0.88	0.6	0.84	0.8	0.76	0.89	0.91	0.58	0.8	0.68	0.82	0.95	0.82	0.95
Other Liab	0.36	0.94	0.95	0.9	0.83	0.8		0.7	0.96	0.65	0.92	0.52	0.97	0.69	0.73	0.95	0.4	0.89	0.94	0.11	0.96	0.89	0.88	0.89	0.96	0.87
Property Plant And Equipment Net	0.41	0.79	0.7	0.7	0.54	0.86	0.7		0.71	0.86	0.68	0.43	0.79	0.28	0.69	0.72	0.51	0.74	0.78	0.45	0.73	0.66	0.65	0.8	0.71	0.85
Net Debt	0.3	0.97	0.99	0.96	0.87	0.78	0.96	0.71		0.59	0.96	0.55	0.98	0.68	0.82	0.99	0.42	0.93	0.95	0.12	0.99	0.95	0.93	0.91	0.99	0.88
Retained Earnings	0.4	0.75	0.61	0.65	0.61	0.93	0.65	0.86	0.59		0.61	0.55	0.72	0.45	0.68	0.61	0.72	0.74	0.76	0.69	0.61	0.44	0.64	0.8	0.63	0.87
Accounts Payable	0.35	0.96	0.97	0.97	0.92	0.81	0.92	0.68	0.96	0.61		0.66	0.96	0.79	0.88	0.97	0.52	0.96	0.95	0.17	0.96	0.92	0.96	0.93	0.98	0.9
Cash	0.51	0.69	0.65	0.73	0.79	0.7	0.52	0.43	0.55	0.55	0.66		0.61	0.7	0.85	0.62	0.88	0.78	0.7	0.43	0.61	0.47	0.72	0.76	0.65	0.68
Non Current Assets Total	0.42	0.99	0.97	0.95	0.86	0.88	0.97	0.79	0.98	0.72	0.96	0.61		0.67	0.83	0.98	0.5	0.95	0.99	0.21	0.98	0.91	0.92	0.96	0.98	0.93
Non Currrent Assets Other	0.19	0.71	0.73	0.76	0.92	0.6	0.69	0.28	0.68	0.45	0.79	0.7	0.67		0.76	0.68	0.63	0.79	0.7	0.33	0.66	0.56	0.83	0.71	0.72	0.72
Other Assets	0.32	0.89	0.87	0.93	0.92	0.84	0.73	0.69	0.82	0.68	0.88	0.85	0.83	0.76		0.85	0.81	0.94	0.86	0.49	0.83	0.76	0.93	0.91	0.86	0.9
Long Term Debt	0.35	0.98	1.0	0.97	0.87	0.8	0.95	0.72	0.99	0.61	0.97	0.62	0.98	0.68	0.85		0.47	0.95	0.96	0.12	1.0	0.95	0.94	0.93	1.0	0.88
Cash And Short Term Investments	0.4	0.61	0.51	0.61	0.71	0.76	0.4	0.51	0.42	0.72	0.52	0.88	0.5	0.63	0.81	0.47		0.7	0.59	0.81	0.45	0.3	0.65	0.71	0.5	0.71
Net Receivables	0.41	0.98	0.96	0.98	0.95	0.89	0.89	0.74	0.93	0.74	0.96	0.78	0.95	0.79	0.94	0.95	0.7		0.97	0.37	0.94	0.83	0.97	0.98	0.96	0.95
Good Will	0.49	0.99	0.96	0.96	0.88	0.91	0.94	0.78	0.95	0.76	0.95	0.7	0.99	0.7	0.86	0.96	0.59	0.97		0.27	0.97	0.86	0.92	0.98	0.97	0.94
Short Term Investments	0.12	0.3	0.17	0.26	0.38	0.58	0.11	0.45	0.12	0.69	0.17	0.43	0.21	0.33	0.49	0.12	0.81	0.37	0.27		0.11	-0.02	0.34	0.4	0.16	0.51
Non Current Liabilities Total	0.36	0.98	0.99	0.96	0.86	0.8	0.96	0.73	0.99	0.61	0.96	0.61	0.98	0.66	0.83	1.0	0.45	0.94	0.97	0.11		0.95	0.93	0.93	1.0	0.88
Inventory	0.22	0.89	0.94	0.89	0.77	0.68	0.89	0.66	0.95	0.44	0.92	0.47	0.91	0.56	0.76	0.95	0.3	0.83	0.86	-0.02	0.95		0.87	0.82	0.94	0.77
Other Current Assets	0.29	0.95	0.96	0.98	0.97	0.82	0.88	0.65	0.93	0.64	0.96	0.72	0.92	0.83	0.93	0.94	0.65	0.97	0.92	0.34	0.93	0.87		0.93	0.95	0.91
Other Stockholder Equity	0.53	0.98	0.94	0.96	0.9	0.95	0.89	0.8	0.91	0.8	0.93	0.76	0.96	0.71	0.91	0.93	0.71	0.98	0.98	0.4	0.93	0.82	0.93		0.94	0.96
Total Liab	0.36	0.98	1.0	0.98	0.9	0.82	0.96	0.71	0.99	0.63	0.98	0.65	0.98	0.72	0.86	1.0	0.5	0.96	0.97	0.16	1.0	0.94	0.95	0.94		0.9
Property Plant And Equipment Gross	0.36	0.95	0.9	0.91	0.87	0.95	0.87	0.85	0.88	0.87	0.9	0.68	0.93	0.72	0.9	0.88	0.71	0.95	0.94	0.51	0.88	0.77	0.91	0.96	0.9

Click cells to compare fundamentals

Jazz Pharmaceuticals Account Relationship Matchups

High Positive Relationship

Long Term Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Long Term Debt
Total Liab	+ 1.0	Long Term Debt
Total Liab	+ 1.0	Non Current Liabilities Total
Non Current Assets Total	+ 0.99	Total Assets

High Negative Relationship

Inventory

- 0.02

Short Term Investments

Jazz Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	57.6M	56.5M	59.7M	62.5M	72.1M	51.5M
Total Assets	5.5B	6.5B	12.3B	10.8B	11.4B	12.0B
Short Long Term Debt Total	1.8B	2.2B	6.1B	5.8B	5.8B	6.1B
Other Current Liab	278.8M	377.9M	675.9M	811.0M	774.5M	813.2M
Total Current Liabilities	364.5M	653.7M	809.3M	933.2M	1.5B	1.6B
Total Stockholder Equity	3.1B	3.7B	4.0B	3.1B	3.7B	3.9B
Other Liab	337.7M	233.9M	1.4B	1.0B	1.2B	1.3B
Property Plant And Equipment Net	270.9M	257.1M	343.4M	301.4M	235.0M	119.6M
Net Debt	1.1B	1.2B	5.5B	4.9B	4.6B	4.8B
Retained Earnings	1.1B	1.2B	830.2M	733.6M	878.7M	922.6M
Accounts Payable	47.5M	26.9M	100.3M	90.8M	102.8M	107.9M
Cash	637.3M	1.1B	591.4M	881.5M	1.2B	1.3B
Non Current Assets Total	3.9B	3.7B	9.7B	8.2B	8.1B	8.5B
Non Currrent Assets Other	47.9M	25.7M	40.8M	58.9M	240.7M	252.8M
Other Assets	272.2M	415.0M	363.9M	435.1M	500.4M	525.4M
Long Term Debt	1.6B	1.8B	6.0B	5.7B	5.1B	5.4B
Cash And Short Term Investments	1.1B	2.1B	591.4M	881.5M	1.6B	1.7B
Net Receivables	356.0M	396.5M	563.4M	651.5M	705.8M	741.1M
Good Will	920.0M	958.3M	1.8B	1.7B	1.8B	1.8B
Short Term Investments	515M	440M	1.1B	30M	420M	441M
Liabilities And Stockholders Equity	5.5B	6.5B	12.3B	10.8B	11.4B	12.0B
Non Current Liabilities Total	2.1B	2.2B	7.5B	6.8B	6.1B	6.4B
Inventory	78.6M	95.4M	1.1B	714.1M	597.0M	626.9M
Other Current Assets	78.9M	152.5M	252.4M	267.2M	334.8M	351.5M
Other Stockholder Equity	2.3B	2.6B	3.5B	3.5B	3.7B	3.9B
Total Liab	2.4B	2.9B	8.3B	7.7B	7.7B	8.0B
Property Plant And Equipment Gross	270.9M	257.1M	343.4M	301.4M	368.3M	386.8M
Total Current Assets	1.6B	2.8B	2.6B	2.6B	3.3B	3.4B
Accumulated Other Comprehensive Income	(223.4M)	(134.4M)	(400.4M)	(1.1B)	(841.7M)	(799.6M)
Intangible Assets	2.4B	2.2B	7.2B	5.8B	5.4B	5.7B
Property Plant Equipment	270.9M	127.9M	343.4M	301.4M	346.6M	363.9M
Current Deferred Revenue	4.7M	2.5M	2.1M	463K	35.1M	36.8M
Net Tangible Assets	(250.0M)	648.7M	(5.0B)	(4.3B)	(3.9B)	(3.7B)
Capital Surpluse	2.3B	2.6B	3.5B	3.5B	4.0B	2.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

S	SentinelOne
GOOG	Alphabet Inc Class C
C	Citigroup

When determining whether Jazz Pharmaceuticals PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:

How To Invest In Jazz

Details

Is Jazz Stock a good investment?

Details

What is Jazz Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Note that the Jazz Pharmaceuticals PLC information on this page should be used as a complementary analysis to other Jazz Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Jazz Stock analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

Is Jazz Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. If investors know Jazz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jazz Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.757

Earnings Share

4.83

Revenue Per Share

60.956

Quarterly Revenue Growth

0.01

Return On Assets

0.0407

The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jazz Cost Of Revenue vs Reconciled Depreciation Analysis

Cost Of Revenue vs Reconciled Depreciation

Cost Of Revenue vs Reconciled Depreciation Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Reconciled Depreciation

Jazz Pharmaceuticals fundamental ratios Correlations

Jazz Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jazz Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Jazz Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY